EUROLAB
usp-1090-assessment-of-drug-product-performance-post-stability
Stability Studies (ICH Guidelines) BP Appendix XVI Stability of Finished Products with PreservativesBP Stability Evaluation of Modified Release PreparationsEMA CHMP/QWP/609/2014 Quality Requirements for Stability of BiosimilarsEMA CPMP/QWP/122/02 Stability Testing for Transdermal PatchesEMA Guideline for Stability of Veterinary Medicinal ProductsEMA Guideline on Holding Times for Bulk Products (Stability Implication)EMA Guideline on Stability Testing for Liposomal Drug FormulationsEMA Guideline on Stability Testing for Orally Inhaled ProductsEMA Reflection Paper on Stability for Polymers in Drug DeliveryEMA Reflection Paper on Stability of Advanced Therapies (ATMPs)EMA Stability Testing for Nanoparticle FormulationsEMA Stability Testing in Pediatric FormulationsEMA Stability Testing of Drug-Device Combination ProductsEP 1.2.1 Drug Substance Stability in Multisource SubmissionsEP 2.9.5 Uniformity of Mass Post-Stability TestingEP 3.2.1 Container Closure System Stability EvaluationEP 5.20 Climatic Conditions in Stability Storage ChambersEP 6.0 Stability Testing Requirements for MonographsEP 6.1 Real-Time Stability Testing of Biological ExtractsEP Climatic Zones IVa and IVb for ASEAN and African MarketsFDA 21 CFR 211.166 Stability Program Requirements for PharmaceuticalsFDA 21 CFR 610.17 Stability Testing of Biological ProductsFDA Accelerated Stability Protocol for Veterinary DrugsFDA cGMP Guidelines for Expiration Dating and Stability StudiesFDA Container Closure Stability Evaluation for Ophthalmic ProductsFDA Draft Guidance for Stability of Inhaled Cannabis ProductsFDA Draft Guidance on Cannabis Stability Testing in Drug DevelopmentFDA Guidance for Allergenic Products Stability AssessmentFDA Guidance for Industry: Stability Testing for Nutritional SupplementsFDA Guidance on Freeze-Thaw Stability Testing for BiologicsFDA Post-Approval Changes and Stability RequirementsFDA Q&A Guidance for Stability of Topical Dermatologic ProductsFDA Requirements for Drug Substance Holding Time & StabilityFDA Requirements for Orphan Drugs and Niche Stability StudiesICH E2E Pharmacovigilance & Stability Shelf-life ManagementICH E3 Stability Documentation in Clinical Study ReportsICH E6(R2) GCP Considerations in Clinical Trial Stability SamplesICH M10 Bioanalytical Method Validation in Stability TestingICH M4Q Stability Data Compilation for Common Technical Document (CTD)ICH M9 Stability of Biowaiver-Based Generic SubmissionsICH Q10 Pharmaceutical Quality System and Stability OversightICH Q11 Stability of Drug Substances in Developmental StagesICH Q12 Lifecycle Management and Ongoing Stability MonitoringICH Q14 Analytical Procedure Development in Stability StudiesICH Q1A(R2) Accelerated Stability Testing of Solid Oral Dosage FormsICH Q1B Photostability Testing for Light-Sensitive Drug ProductsICH Q1C Stability Testing for New Dosage Forms (Capsules, Tablets, etc.)ICH Q1D Bracketing and Matrixing Design Stability Protocol DevelopmentICH Q1E Evaluation of Stability Data for Regulatory SubmissionsICH Q1F Stability Data Requirements for Global RegistrationICH Q2(R1) Validation of Analytical Procedures in Stability StudiesICH Q3B(R2) Stability Testing of Impurities in Drug ProductsICH Q3C Residual Solvent Stability in Finished Dosage FormsICH Q4 Guidelines for Pharmacopoeial Stability HarmonizationICH Q4B Annex Stability-Related Harmonization for Global FilingICH Q5C Stability Testing of Biotechnological/Biological ProductsICH Q5D Derivation and Stability of Cell SubstratesICH Q6B Specifications Testing for Biotech Products in Long-Term StudiesICH Q8 Design Space for Stability-Critical ParametersICH Q9 Risk-Based Stability Planning and Protocol DesignICH S3B Photostability of Biologics in Animal StudiesICH S4 Stability of New Veterinary Drug Substances and ProductsICH S6(R1) Preclinical Stability of Biotech ProductsISO 10993-1 Biocompatibility Stability Studies in Medical DevicesISO 11607 Package Integrity Stability for Sterile Medical DevicesISO 13408 Stability Testing of Aseptic Processing SystemsISO 14644 Environmental Monitoring for Stability ChambersISO 14971 Risk Management Related to Stability FailuresISO 15378 GMP for Primary Packaging Stability InteractionsISO 17025 Stability Testing Accreditation RequirementsISO 17034 Reference Material Stability and HomogeneityISO 20387 Stability Assessment in Biobanking Sample StorageISO 21973 Transport Stability of Cell-Based TherapiesISO 9001:2015 Quality System Requirements for Stability ProgramsUSP <1046> Cellular and Gene Therapy Product StabilityUSP <1049> Excipient Stability and Shelf-Life EvaluationUSP <1079> Storage and Stability Testing in Distribution SystemsUSP <1086> Impurities Testing within Stability ProtocolsUSP <1118> Monitoring Stability in Storage and Transport ConditionsUSP <1168> Stability Testing for RadiopharmaceuticalsUSP <1191> Stability Considerations in Compounding Pharmacy ProductsUSP <1224> Transfer of Analytical Procedures in Stability StudiesUSP <1225> Validation of Compendial Procedures in Stability ContextUSP <1226> Verification of Compendial Procedures Post-StabilityUSP <671> Stability Testing of Packaging MaterialsUSP <795> Stability Evaluation of Nonsterile PreparationsUSP <797> Stability Testing of Sterile Preparations in CleanroomsWHO Annex 10 Stability Testing of Active Pharmaceutical IngredientsWHO Annex 7 Stability of Reconstituted Lyophilized ProductsWHO Annex 9 Stability for Zoonotic Biological ProductsWHO Good Storage and Distribution Practices for StabilityWHO Guidelines for Stability of DNA and mRNA VaccinesWHO Guidelines on Stability of Combination ARV TherapiesWHO Stability of Monoclonal Antibodies Under Accelerated ConditionsWHO Stability Requirements for Medical Oxygen and InhalersWHO Stability Testing for Pre-Filled Syringes and Auto-InjectorsWHO Temperature Mapping and Qualification of Stability ChambersWHO TRS 1003 Stability Protocols for Combination ProductsWHO TRS 1010 Stability Testing for Vaccines under Cold Chain ConditionsWHO TRS 1019 Stability Testing of Blood and Blood ProductsWHO TRS 953 Climatic Zone-Based Stability Testing for Global MarketsWHO TRS 970 Real-Time Stability Assessment for WHO PrequalificationWHO TRS 992 Long-Term Stability Testing for Herbal Medicinal Products

USP <1090> Assessment of Drug Product Performance Post Stability Laboratory Testing Service: A Comprehensive Guide

Standard-Related Information

The USP <1090> Assessment of Drug Product Performance Post Stability laboratory testing service is governed by various international and national standards that ensure the quality, safety, and efficacy of pharmaceutical products. This section provides an in-depth overview of the relevant standards, their evolution, and compliance requirements.

Overview of Relevant Standards

  • ISO 11133:2014: This standard specifies the general principles for assessing the stability of medicinal products.
  • USP <1090>: The United States Pharmacopeia (USP) monograph provides guidelines for evaluating the performance of drug products post-stability testing.
  • ASTM E2279-09: The American Society for Testing and Materials (ASTM) standard focuses on the evaluation of drug product stability.
  • International and National Standards

    International standards:

  • ISO 13485:2016: This standard specifies requirements for a quality management system in medical device manufacturing, which includes pharmaceutical products.
  • EU GMP Annex 1: The European Unions Good Manufacturing Practice (GMP) guidelines outline the principles for ensuring the quality of medicinal products.
  • National standards:

  • US FDA Guidance for Industry: Stability Testing of Drug Substances and Products QIA S2(R1): This guidance provides recommendations for stability testing in pharmaceutical manufacturing.
  • Japanese Pharmacopeia (JP) 32: The JP monograph outlines requirements for the evaluation of drug product stability.
  • Standard Development Organizations

    Standard development organizations play a crucial role in creating, maintaining, and updating standards:

  • International Organization for Standardization (ISO): ISO develops and publishes international standards.
  • American Society for Testing and Materials (ASTM): ASTM creates and maintains standards for various industries, including pharmaceuticals.
  • European Committee for Standardization (CEN): CEN is responsible for developing European standards.
  • Evolution of Standards

    Standards evolve through a continuous process:

    1. Revision: Existing standards are reviewed and updated to reflect new technologies, scientific advancements, or regulatory changes.

    2. New publication: New standards are developed to address emerging needs or issues.

    3. Harmonization: Standards are aligned with international or regional requirements.

    Standard Numbers and Scope

    Relevant standard numbers and their scope:

  • ISO 11133:2014: Stability testing of pharmaceutical products
  • USP <1090>: Post-stability performance evaluation of drug products
  • ASTM E2279-09: Evaluation of drug product stability
  • Compliance Requirements

    Compliance requirements for different industries:

  • Pharmaceuticals: Manufacturers must adhere to USP, JP, and EU GMP guidelines.
  • Medical Devices: Device manufacturers must comply with ISO 13485:2016 and EU MDR.
  • Standard Requirements and Needs

    The USP <1090> Assessment of Drug Product Performance Post Stability testing service is essential for ensuring the quality, safety, and efficacy of pharmaceutical products. This section explains why this test is necessary, required, and beneficial.

    Need for Testing

    This specific test is required to:

    1. Ensure stability: Evaluate the performance of drug products over time.

    2. Maintain product quality: Prevent degradation or contamination that may compromise safety.

    3. Comply with regulations: Adhere to international and national standards.

    Business and Technical Reasons for Testing

    Business reasons:

  • Product liability: Manufacturers can minimize liability risks by demonstrating the stability of their products.
  • Market competitiveness: Companies can differentiate themselves by offering high-quality, stable products.
  • Regulatory compliance: Compliance with regulations ensures market access and trade facilitation.
  • Technical reasons:

  • Stability testing: Evaluates product performance over time, ensuring safety and efficacy.
  • Quality control: Prevents degradation or contamination that may compromise product quality.
  • Consequences of Not Performing the Test

    Consequences of not performing the USP <1090> Assessment of Drug Product Performance Post Stability testing service:

    1. Regulatory issues: Non-compliance with regulations can lead to market access and trade restrictions.

    2. Product liability: Manufacturers may be held liable for product-related issues.

    3. Reputation damage: Companies that fail to ensure product quality risk damaging their reputation.

    Industries and Sectors Requiring the Test

    The USP <1090> Assessment of Drug Product Performance Post Stability testing service is essential for various industries:

  • Pharmaceuticals: Manufacturers must evaluate the stability of their products.
  • Medical Devices: Device manufacturers need to ensure the quality of their products.
  • Risk Factors and Safety Implications

    Risk factors and safety implications:

    1. Product contamination: Failure to maintain product stability can lead to contamination, compromising safety.

    2. Degradation: Degradation or deterioration of products over time may compromise efficacy or pose health risks.

    3. Regulatory non-compliance: Manufacturers risk facing regulatory issues if they fail to ensure product quality.

    Standard-Related Information

    The USP <1090> Assessment of Drug Product Performance Post Stability laboratory testing service is governed by various international and national standards that ensure the quality, safety, and efficacy of pharmaceutical products. This section provides an in-depth overview of the relevant standards, their evolution, and compliance requirements.

    Overview of Relevant Standards

  • ISO 11133:2014: This standard specifies the general principles for assessing the stability of medicinal products.
  • USP <1090>: The United States Pharmacopeia (USP) monograph provides guidelines for evaluating the performance of drug products post-stability testing.
  • ASTM E2279-09: The American Society for Testing and Materials (ASTM) standard focuses on the evaluation of drug product stability.
  • International and National Standards

    International standards:

  • ISO 13485:2016: This standard specifies requirements for a quality management system in medical device manufacturing, which includes pharmaceutical products.
  • EU GMP Annex 1: The European Unions Good Manufacturing Practice (GMP) guidelines outline the principles for ensuring the quality of medicinal products.
  • National standards:

  • US FDA Guidance for Industry: Stability Testing of Drug Substances and Products QIA S2(R1): This guidance provides recommendations for stability testing in pharmaceutical manufacturing.
  • Japanese Pharmacopeia (JP) 32: The JP monograph outlines requirements for the evaluation of drug product stability.
  • Standard Development Organizations

    Standard development organizations play a crucial role in creating, maintaining, and updating standards:

  • International Organization for Standardization (ISO): ISO develops and publishes international standards.
  • American Society for Testing and Materials (ASTM): ASTM creates and maintains standards for various industries, including pharmaceuticals.
  • European Committee for Standardization (CEN): CEN is responsible for developing European standards.
  • Evolution of Standards

    Standards evolve through a continuous process:

    1. Revision: Existing standards are reviewed and updated to reflect new technologies, scientific advancements, or regulatory changes.

    2. New publication: New standards are developed to address emerging needs or issues.

    3. Harmonization: Standards are aligned with international or regional requirements.

    Standard Numbers and Scope

    Relevant standard numbers and their scope:

  • ISO 11133:2014: Stability testing of pharmaceutical products
  • USP <1090>: Post-stability performance evaluation of drug products
  • ASTM E2279-09: Evaluation of drug product stability
  • Compliance Requirements

    Compliance requirements for different industries:

  • Pharmaceuticals: Manufacturers must adhere to USP, JP, and EU GMP guidelines.
  • Medical Devices: Device manufacturers must comply with ISO 13485:2016 and EU MDR.
  • Standard Requirements and Needs

    The USP <1090> Assessment of Drug Product Performance Post Stability testing service is essential for ensuring the quality, safety, and efficacy of pharmaceutical products. This section explains why this test is necessary, required, and beneficial.

    Need for Testing

    This specific test is required to:

    1. Ensure stability: Evaluate the performance of drug products over time.

    2. Maintain product quality: Prevent degradation or contamination that may compromise safety.

    3. Comply with regulations: Adhere to international and national standards.

    Business and Technical Reasons for Testing

    Business reasons:

  • Product liability: Manufacturers can minimize liability risks by demonstrating the stability of their products.
  • Market competitiveness: Companies can differentiate themselves by offering high-quality, stable products.
  • Regulatory compliance: Compliance with regulations ensures market access and trade facilitation.
  • Technical reasons:

  • Stability testing: Evaluates product performance over time, ensuring safety and efficacy.
  • Quality control: Prevents degradation or contamination that may compromise product quality.
  • Consequences of Not Performing the Test

    Consequences of not performing the USP <1090> Assessment of Drug Product Performance Post Stability testing service:

    1. Regulatory issues: Non-compliance with regulations can lead to market access and trade restrictions.

    2. Product liability: Manufacturers may be held liable for product-related issues.

    3. Reputation damage: Companies that fail to ensure product quality risk damaging their reputation.

    Industries and Sectors Requiring the Test

    The USP <1090> Assessment of Drug Product Performance Post Stability testing service is essential for various industries:

  • Pharmaceuticals: Manufacturers must evaluate the stability of their products.
  • Medical Devices: Device manufacturers need to ensure the quality of their products.
  • Risk-Based Approach

    A risk-based approach can be used to identify and mitigate potential risks associated with product instability. This involves identifying critical parameters that affect product stability, assessing the likelihood and impact of instability, and implementing controls to minimize these risks.

    Standards for Stability Testing

    Several standards provide guidelines for stability testing:

  • ISO 11133:2014: General principles for assessing stability
  • USP <1090>: Guidelines for evaluating post-stability performance
  • ASTM E2279-09: Standard practice for evaluating drug product stability
  • Quality Control Measures

    To ensure product quality, manufacturers can implement the following measures:

  • Regular testing: Conduct regular tests to evaluate product stability.
  • Process validation: Validate production processes to ensure they meet quality and regulatory requirements.
  • Continuous monitoring: Continuously monitor product performance during storage and transportation.
  • By understanding the standards, risks, and quality control measures involved in stability testing, manufacturers can ensure that their products are safe, effective, and comply with regulatory requirements.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers